Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Protein-Tyrosine Kinases
  • Pyrimidines

abstract

  • After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)

authors

publication date

  • December 7, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa062867

PubMed ID

  • 17151364

Additional Document Info

start page

  • 2408

end page

  • 17

volume

  • 355

number

  • 23